Navigation Links
Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
Date:8/20/2007

CHAPEL HILL A patients expectations about the side effects of chemotherapy usually focus on nausea, hair loss, fatigue and other side effects. Worries about severe allergic reactions to their therapy is usually not a concern.

A recent study from the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, the Vanderbilt-Ingram Comprehensive Cancer Center and the Sarah Canon Cancer Center in Nashville have identified an unusually high rate of allergic reaction in cancer patients living in the middle South who received a common drug used for treating their cancer.

This study was presented at the 43rd annual meeting of the American Society of Clinical Oncology in Chicago in June, 2007 and appears online Aug. 17th in the Journal of Clinical Oncology.

The drug, cetuximab, marketed by Bristol-Meyers Squibb as Erbitux, is a widely used chemotherapeutic agent for treating colon cancer, head and neck tumors, and is being studied in the treatment of ovarian, lung, breast and gastrointestinal tumors.

When cetuximab was first approved, the first three patients treated at UNC had severe reactions to the drug. Doctors at both Sarah Canon and Vanderbilt also had more patients than expected react with a drop in blood pressure and shortness of breath or other hypersensitivity reactions within minutes of infusion of cetuximab.

After speaking with others, we realized that patients who lived on a line across North Carolina, Tennessee, northern Arkansas and southern Missouri had these adverse reactions to the drug, said study leader Dr. Bert ONeil, assistant professor of medicine, division of hematology and oncology at UNC. So, we thought it appropriate to see what common bonds were there.

Cancer researchers from UNC and Vanderbilt pooled their patients dating back to when the drug received approval from the Food and Drug Administration, in 2004. More than 140 patients from ongoing clinical trials (at Vanderbilt) and current clinical records (at UNC) were reviewed for the presence of immediate, severe hypersensitivity reactions as well as pertinent demographics to determine this regions rate of allergic reactions and to see if a profile of the potentially allergic patient was evident.

The nationwide rate of severe allergic reactions to cetuximab is only about 2 percent. However, 22 percent of patients in this study showed severe allergic reactions to the drug. Cetuximab normally is infused over a two-hour period, but allergic patients had a reaction within minutes of starting the infusion, a classic anaphylactic reaction. The strongest predictor of a reaction to cetuximab was a history of other hypersensitivities, such as allergic asthma, food allergies, bee stings or allergies to other drugs, such as penicillin.

What is it about this strip across the middle South" A good question, said ONeil. The most likely places to look would be food- or plant-based allergens. If it is of plant origin, finding the source could be a needle-in-a-haystack search. And its a narrow geographic band; colleagues in Atlanta or the University of Virginia havent seen this type of reaction.

The research team felt that clinicians in this middle South region must obtain a thorough history of allergic reaction and be prepared to use an alternative drug, such as panitumimab, for patients with a history of hypersensitivity reactions, ONeil said.

Bristol-Myers Squibb is studying a screening test for the specific factor that leads to the reaction. In the meantime, doctors in the middle South need to be aware of, and be prepared to treat, sudden, severe allergic reactions when using cetuximab, ONeil said.

Based on the results of this study, UNC has a physician, physician assistant or nurse practitioner present for the first 30 minutes of all infusions of cetuximab. The Sarah Cannon Cancer Center halted all studies the drug.

This is a curious problem, but not a problem we cant deal with, said ONeil. As long as we know the patients allergy history, we know what to do.


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-843-9687
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Nobel Prize for Medicine shared by Three scientists
2. Scientists plan human cloning clinic in the United States
3. Scientists crack dengue fever puzzle
4. Scientists found ancient Human Germ Killer
5. Scientists locate key hormone involved in appetite control
6. Scientists open the book of life
7. Electronic nose by Italian scientists
8. Scientists review SARS
9. Scientists push to lower hidden sodium in food
10. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
11. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates ... leading ERP expert that specializes in long-term care, Brooke Grove now has the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Vivify Health, the pioneer and market leader of remote ... significant patent for the advancement of healthcare delivery from ... health.  This landmark patent provides the company with broad ... position as the leader in remote care.  ... to apply consumer mobile devices, wireless biometrics, EMR integration ...
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
Breaking Medicine Technology: